Scroll

zuclopenthixol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2877	53772-83-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: zuclopenthixol (Z)-Clopenthixol cisordinol clopixol zuclopenthixol dihydrochloride zuclopenthixol hydrochloride zuclopenthixol HCl	Zuclopenthixol is a potent neuroleptic of the thioxanthene series with a piperazine side-chain. The antipsychotic effect of neuroleptics is related to their dopamine receptor blocking effect. The thioxanthenes have a high affinity for both the adenylate cyclase coupled dopamine D1 receptors and for the dopamine D2 receptors; in the phenothiazine group the affinity for D1 receptors is much lower than that for D2 receptors, whereas butyrophenones, diphenylbutylpiperidines and benzamides only have affinity for D2 receptors. Molecular weight: 400.97 Formula: C22H25ClN2OS CLOGP: 4.13 LIPINSKI: 0 HAC: 3 HDO: 1 TPSA: 26.71 ALOGS: -5.19 ROTB: 5

Molecule

Description

Molfile Inchi Smiles

Synonyms:

zuclopenthixol
(Z)-Clopenthixol
cisordinol
clopixol
zuclopenthixol dihydrochloride
zuclopenthixol hydrochloride
zuclopenthixol HCl

Zuclopenthixol is a potent neuroleptic of the thioxanthene series with a piperazine side-chain. The antipsychotic effect of neuroleptics is related to their dopamine receptor blocking effect. The thioxanthenes have a high affinity for both the adenylate cyclase coupled dopamine D1 receptors and for the dopamine D2 receptors; in the phenothiazine group the affinity for D1 receptors is much lower than that for D2 receptors, whereas butyrophenones, diphenylbutylpiperidines and benzamides only have affinity for D2 receptors.

Molecular weight: 400.97
Formula: C22H25ClN2OS
CLOGP: 4.13
LIPINSKI: 0
HAC: 3
HDO: 1
TPSA: 26.71
ALOGS: -5.19
ROTB: 5

Drug dosage:

Dose	Unit	Route
30	mg	O
15	mg	P
30	mg	P

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	3.56 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	49 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
None	UK Medicines and Healthcare Products Regulatory Agency (MHRA)

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood prolactin abnormal	871.84	53.21	158	4739	2921	63481204
Anosognosia	865.96	53.21	158	4739	3038	63481087
Sexual dysfunction	848.02	53.21	163	4734	4196	63479929
Disturbance in social behaviour	830.84	53.21	158	4739	3835	63480290
Metabolic disorder	782.98	53.21	163	4734	6340	63477785
Personality change	697.47	53.21	150	4747	6823	63477302
Dystonia	580.48	53.21	147	4750	13672	63470453
Sedation	538.92	53.21	174	4723	38635	63445490
Dyskinesia	525.13	53.21	163	4734	31839	63452286
Suicide attempt	465.76	53.21	175	4722	60743	63423382
Blood glucose increased	359.18	53.21	159	4738	83597	63400528
Insurance issue	174.55	53.21	48	4849	6073	63478052
Intentional self-injury	140.15	53.21	58	4839	25629	63458496
Refusal of examination	130.29	53.21	21	4876	182	63483943
Eosinophil count decreased	115.34	53.21	28	4869	2162	63481963
Condition aggravated	104.75	53.21	141	4756	402076	63082049
Schizophrenia	95.77	53.21	34	4863	9918	63474207
Personality change due to a general medical condition	87.22	53.21	15	4882	199	63483926
Drug ineffective	84.61	53.21	221	4676	1044544	62439581
Adverse drug reaction	67.54	53.21	53	4844	79661	63404464
Intentional overdose	66.52	53.21	51	4846	74101	63410024
Electrocardiogram QT prolonged	57.93	53.21	43	4854	59487	63424638
Mean cell haemoglobin decreased	54.81	53.21	19	4878	5160	63478965

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood prolactin abnormal	205.46	36.85	43	4794	926	34951168
Dystonia	200.97	36.85	70	4767	10775	34941319
Anosognosia	199.52	36.85	42	4795	931	34951163
Schizophrenia	184.21	36.85	62	4775	8604	34943490
Disturbance in social behaviour	172.63	36.85	42	4795	1809	34950285
Sexual dysfunction	149.52	36.85	49	4788	6254	34945840
Metabolic disorder	137.73	36.85	42	4795	4241	34947853
Psychotic disorder	136.85	36.85	67	4770	24385	34927709
Delusion of grandeur	132.42	36.85	31	4806	1129	34950965
Personality change	122.07	36.85	40	4797	5099	34946995
Neuroleptic malignant syndrome	118.18	36.85	55	4782	17879	34934215
Sedation	112.87	36.85	56	4781	20950	34931144
Psychotic symptom	91.33	36.85	25	4812	1718	34950376
Dyskinesia	89.56	36.85	49	4788	22364	34929730
Hallucination, auditory	89.35	36.85	40	4797	11877	34940217
Self-injurious ideation	87.52	36.85	24	4813	1660	34950434
Affective disorder	83.99	36.85	29	4808	4331	34947763
Rhinalgia	83.58	36.85	21	4816	1032	34951062
Myocarditis	81.02	36.85	39	4798	13643	34938451
Delusion	80.88	36.85	38	4799	12597	34939497
Extrapyramidal disorder	80.19	36.85	38	4799	12842	34939252
Suicide attempt	71.29	36.85	52	4785	39064	34913030
Aggression	66.96	36.85	50	4787	38914	34913180
Lymphocyte count abnormal	66.57	36.85	18	4819	1180	34950914
Salivary hypersecretion	64.74	36.85	29	4808	8615	34943479
Paranoia	55.53	36.85	29	4808	12039	34940055
Neutrophil count increased	53.72	36.85	32	4805	17114	34934980
Lymphocyte count decreased	50.33	36.85	34	4803	22588	34929506
Hypothermia	49.94	36.85	26	4811	10722	34941372
Patient restraint	49.78	36.85	9	4828	86	34952008
Priapism	48.04	36.85	20	4817	4974	34947120
SARS-CoV-2 test positive	47.94	36.85	21	4816	5912	34946182
Antipsychotic drug level decreased	46.00	36.85	13	4824	1004	34951090
Blepharospasm	44.55	36.85	13	4824	1125	34950969
Nasal discomfort	44.06	36.85	14	4823	1614	34950480
Blood glucose increased	43.87	36.85	50	4787	66668	34885426
Pharyngeal dystonia	38.43	36.85	7	4830	70	34952024

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood prolactin abnormal	947.77	34.90	184	8612	3417	79732175
Anosognosia	933.53	34.90	183	8613	3581	79732011
Disturbance in social behaviour	888.63	34.90	184	8612	4786	79730806
Sexual dysfunction	839.32	34.90	190	8606	7573	79728019
Metabolic disorder	797.32	34.90	188	8608	8982	79726610
Personality change	706.51	34.90	174	8622	9996	79725596
Dystonia	688.04	34.90	199	8597	21200	79714392
Dyskinesia	547.37	34.90	200	8596	44573	79691019
Sedation	536.56	34.90	205	8591	51690	79683902
Suicide attempt	443.80	34.90	205	8591	82727	79652865
Blood glucose increased	341.51	34.90	191	8605	114784	79620808
Schizophrenia	261.28	34.90	88	8708	15352	79720240
Insurance issue	182.50	34.90	53	8743	5680	79729912
Psychotic disorder	136.95	34.90	74	8722	41328	79694264
Delusion of grandeur	132.88	34.90	31	8765	1401	79734191
Neuroleptic malignant syndrome	131.22	34.90	63	8733	27496	79708096
Eosinophil count decreased	128.80	34.90	36	8760	3360	79732232
Refusal of examination	121.27	34.90	21	8775	197	79735395
Delusion	110.49	34.90	51	8745	20372	79715220
Extrapyramidal disorder	105.40	34.90	51	8745	22628	79712964
Hallucination, auditory	100.61	34.90	48	8748	20645	79714947
Drug ineffective	99.84	34.90	302	8494	1080611	78654981
Psychotic symptom	95.06	34.90	27	8769	2670	79732922
Adverse drug reaction	91.07	34.90	68	8728	66324	79669268
Electrocardiogram QT prolonged	88.59	34.90	76	8720	90310	79645282
Intentional self-injury	85.59	34.90	50	8746	32369	79703223
Salivary hypersecretion	84.76	34.90	38	8758	14186	79721406
Aggression	83.15	34.90	58	8738	50900	79684692
Leukopenia	75.75	34.90	78	8718	116435	79619157
Affective disorder	72.11	34.90	29	8767	8290	79727302
Rhinalgia	71.42	34.90	21	8775	2346	79733246
Condition aggravated	71.41	34.90	165	8631	500959	79234633
Personality change due to a general medical condition	67.48	34.90	13	8783	229	79735363
Lymphocyte count abnormal	66.56	34.90	18	8778	1485	79734107
Self-injurious ideation	62.54	34.90	21	8775	3617	79731975
Mental impairment	60.06	34.90	33	8763	19003	79716589
Pain	59.22	34.90	5	8791	703797	79031795
Myocarditis	58.62	34.90	34	8762	21699	79713893
Priapism	54.42	34.90	20	8776	4485	79731107
Neutropenia	52.68	34.90	105	8691	287605	79447987
Mean cell haemoglobin decreased	51.54	34.90	21	8775	6203	79729389
Arthralgia	51.14	34.90	3	8793	571800	79163792
Patient restraint	50.92	34.90	9	8787	96	79735496
Mean cell haemoglobin concentration decreased	50.45	34.90	19	8777	4560	79731032
Dyspnoea	48.71	34.90	17	8779	857008	78878584
Lymphocyte count decreased	44.74	34.90	39	8757	47250	79688342
Neutrophil count increased	44.55	34.90	32	8764	29364	79706228
Paranoia	43.58	34.90	27	8769	19405	79716187
Schizoaffective disorder	43.33	34.90	14	8782	2138	79733454
Agitation	43.03	34.90	54	8742	99661	79635931
Persecutory delusion	42.15	34.90	17	8779	4892	79730700
Nausea	42.12	34.90	27	8769	957169	78778423
Hypothermia	39.69	34.90	27	8769	22719	79712873
Rash	39.36	34.90	8	8788	578350	79157242
Psychomotor hyperactivity	39.29	34.90	24	8772	16825	79718767
Suicidal ideation	38.92	34.90	45	8751	76295	79659297
SARS-CoV-2 test positive	38.86	34.90	21	8775	11695	79723897
Pneumonia	37.63	34.90	13	8783	660233	79075359
Antipsychotic drug level decreased	37.55	34.90	11	8785	1213	79734379
Serositis	36.70	34.90	10	8786	848	79734744

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05AF05	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Thioxanthene derivatives
MeSH PA	D014150	Antipsychotic Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018492	Dopamine Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents
CHEBI has role	CHEBI:37890	alpha-adrenergic receptor blockaders
CHEBI has role	CHEBI:37955	H1 receptor antagonists
CHEBI has role	CHEBI:48279	serotonin antagonists
CHEBI has role	CHEBI:48561	dopaminergic antagonists
CHEBI has role	CHEBI:65190	typical antipsychotic drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Schizophrenia	indication	58214004	DOID:5419

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.19	Basic
pKa2	4.19	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN	ANTAGONIST			WOMBAT-PK	DRUG LABEL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	ANTAGONIST			WOMBAT-PK	DRUG LABEL
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN				WOMBAT-PK
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	6.77	CHEMBL
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN				WOMBAT-PK

External reference:

ID	Source
D03556	KEGG_DRUG
C0376160	UMLSCUI
CHEBI:51364	CHEBI
CHEMBL53904	ChEMBL_ID
D003006	MESH_DESCRIPTOR_UI
DB01624	DRUGBANK_ID
5311507	PUBCHEM_CID
7559	IUPHAR_LIGAND_ID
5443	INN_ID
58045-23-1	SECONDARY_CAS_RN
47ISU063SG	UNII
DB13841	DRUGBANK_ID
102546	RXNORM
004069	NDDF
004072	NDDF
387566002	SNOMEDCT_US
426594007	SNOMEDCT_US
427940003	SNOMEDCT_US
428715002	SNOMEDCT_US
429346008	SNOMEDCT_US
C0009026	UMLSCUI
1315	INN_ID

Pharmaceutical products:

None